Imperial College London

Dr Alexandra Hogan

Faculty of MedicineSchool of Public Health

Imperial College Research Fellow



+44 (0)20 7594 3946a.hogan Website




Norfolk PlaceSt Mary's Campus






BibTex format

author = {Hogan, AB and Campbell, PT and Blyth, CC and Lim, FJ and Fathima, P and Davis, S and Moore, HC and Glass, K},
doi = {10.1016/j.vaccine.2017.09.043},
journal = {Vaccine},
pages = {6172--6179},
title = {Potential impact of a maternal vaccine for RSV: a mathematical modelling study},
url = {},
volume = {35},
year = {2017}

RIS format (EndNote, RefMan)

AB - Respiratory syncytial virus (RSV) is a major cause of respiratory morbidity and one of the main causes of hospitalisation in young children. While there is currently no licensed vaccine for RSV, a vaccine candidate for pregnant women is undergoing phase 3 trials. We developed a compartmental age-structured model for RSV transmission, validated using linked laboratory-confirmed RSV hospitalisation records for metropolitan Western Australia. We adapted the model to incorporate a maternal RSV vaccine, and estimated the expected reduction in RSV hospitalisations arising from such a program. The introduction of a vaccine was estimated to reduce RSV hospitalisations in Western Australia by 6-37% for 0-2month old children, and 30-46% for 3-5month old children, for a range of vaccine effectiveness levels. Our model shows that, provided a vaccine is demonstrated to extend protection against RSV disease beyond the first three months of life, a policy using a maternal RSV vaccine could be effective in reducing RSV hospitalisations in children up to six months of age, meeting the objective of a maternal vaccine in delaying an infant's first RSV infection to an age at which severe disease is less likely.
AU - Hogan,AB
AU - Campbell,PT
AU - Blyth,CC
AU - Lim,FJ
AU - Fathima,P
AU - Davis,S
AU - Moore,HC
AU - Glass,K
DO - 10.1016/j.vaccine.2017.09.043
EP - 6179
PY - 2017///
SN - 0264-410X
SP - 6172
TI - Potential impact of a maternal vaccine for RSV: a mathematical modelling study
T2 - Vaccine
UR -
UR -
UR -
VL - 35
ER -